University of Pavia
Pavia, Lombardy, 27100, Italy
NCT Number: NCT04965948
The present study aims at evaluating the anti-inflammatory effects of a novel food in older adult volunteers. Briefly, this randomized, double-blind and placebo-controlled study is performed on 91 apparently healthy older adults (age≥65 years) before and after 12 weeks' consumption of a snack enriched with camelina Sativa oil. Subjects were randomized into two groups (active group vs placebo group).
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Not applicable
Pavia, Lombardy, 27100, Italy
Ninety-one volunteers (26M/65F) are enrolled according to the following inclusion criteria i) free-living older adults ≥ 65 years; ii) apparently healthy subjects; iii) subjects who do not take vitamin supplements/integration and/or omega 3 polyunsaturated fatty acids; iv) subjects without food allergies.
All volunteers are informed about the purpose of the study and the potential risk and provide their informed consent.
Subjects are randomized into two groups: active group (13M/36F) vs placebo group (13M/29F).
The main objective of this project is to test the efficacy of the 12-weeks consumption of a novel food (snack enriched with camelina Sativa oil) on the inflammatory status in older adults.
The primary and secondary endpoints are:
i) Investigation of changes in serum CRP levels and serum levels of pro- and anti-inflammatory cytokines, in the active group (volunteers consumed enriched snack with camelina Sativa oil) and placebo group, after 12 weeks of snacking (T1), compared to baseline (T0) (primary endpoint).
ii) Evaluation of changes in serum lipid panel parameters after the consumption of the novel food in both the active and placebo groups (secondary endpoint).
iii) Evaluation of changes in glucidic status after the consumption of the novel food in both the active and placebo groups (secondary endpoint).
iv) Evaluation of changes in the levels of omega 3 polyunsaturated fatty acids in both the active and placebo groups (secondary endpoint).
v) Evaluation of the nutritional status at T0 and at T1 in both the active and placebo groups (secondary endpoint).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Consumption of snack enriched with camelina sativa oil, twice a day for 12 weeks
Consumption of placebo snack (no enriched with camelina sativa oil), twice a day for 12 weeks
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Investigation of changes in serum CRP levels (pg/mL) and serum levels of pro- and anti- inflammatory cytokines (TNF-α, pg/mL; TGF-beta1, pg/mL and TGF-beta2, pg/mL; IL-18 pg/mL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of changes in serum lipid panel parameters (total cholesterol, mg/dL; triglycerides, mg/dL; HDL cholesterol, mg/dL; LDL cholesterol, mg/dL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of changes in the levels of omega 3 polyunsaturated fatty acids.
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of changes in the levels of glucose (mg/dL)
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of changes in the levels of insulin (μU/mL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of changes in the levels of glycated haemoglobin (mmol/mol).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of changes in the HOMA index.
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of nutritional status by assessing the serum levels of ALT (U/L), AST (U/L).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of nutritional status by assessing the serum levels of creatinine (mg/dL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of nutritional status by assessing the serum levels of prealbumin (g/L).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of nutritional status by assessing the calcium (mg/dL), magnesium (mg/dL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of nutritional status by assessing the serum levels of iron (μg/dL) and zinc (μg/dL)
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of nutritional status by assessing the serum levels of vitamin B9 (ng/mL) and vitamin D (ng/mL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of nutritional status by assessing the serum levels of vitamin B12 (pg/mL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Evaluation of nutritional status by assessing the serum levels of Homocysteine (μM).
Time frame: Baseline (T0).
Evaluation at baseline of weight (Kg).
Time frame: Baseline (T0).
Evaluation at baseline of height (cm) and waist circumference (cm).
Time frame: Baseline (T0).
Evaluation at baseline of Body Mass Index (Kg/m2) to investigate the prevalence of overweight or obesity.
Time frame: Baseline (T0).
Evaluation at baseline of Waist to height ratio (WHtR) as a proxy of fat distribution and metabolic diseases risk.
Time frame: Baseline (T0).
Evaluation at baseline of reactance (Ohm) and resistance (Ohm) by using vectorial bioimpedance analysis.
Time frame: Baseline (T0).
Evaluation at baseline of muscle strength (Kg) by using a handgrip-dynamometer.
University of Pavia
Other
Evaluation of the Anti-inflammatory Effects of a Snack Enriched With Camelina Sativa Oil in Free-living Older Adults: a Randomized, Double-blind, Placebo-controlled Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06159543
Dyslipidemias, Glucose Metabolism Disorders
Loma Linda, California, United States
View Trial DetailsNCT05295719
Body Weight, Dyslipidemias
Lubbock, Texas, United States
View Trial DetailsNCT05730231
Antioxidative Stress, Behavior
Izola, Slovenia
View Trial DetailsNCT06426017
Advance Glycation, Body Weight
Peshawar, KPK, Pakistan
View Trial Details